Previous 10 | Next 10 |
2024-05-09 17:13:21 ET More on Gilead Sciences, Arcellx Gilead Sciences, Inc. (GILD) Q1 2024 Earnings Call Transcript Gilead Sciences, Inc. 2024 Q1 - Results - Earnings Call Presentation Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern? Gi...
-- The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody -- -- Anito-cel will be manufactured from Kite’s Frederick, Maryland facility for iMMagine-3 as th...
-- The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody -- -- Anito-cel will be manufactured from Kite’s Frederick, Maryland facility for iMMagine-3 as th...
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first quarter ended March 31, 2024. ...
2024-05-02 10:25:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. During the first quarter, Baron Opportunity Fund rose 15.33%, outperforming the broade...
2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Health...
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Th...
2024-03-07 15:15:01 ET Morgan Stanley analyst issues OVERWEIGHT recommendation for ACLX on March 7, 2024 02:52PM ET. ACLX was trading at $71.94 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy reco...
Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference PR Newswire REDWOOD CITY, Calif. , Feb. 29, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunot...
News, Short Squeeze, Breakout and More Instantly...
2024-05-31 06:00:08 ET Biren Amin from Piper Sandler issued a price target of $70.00 for ACLX on 2024-05-31 05:01:00. The adjusted price target was set to $70.00. At the time of the announcement, ACLX was trading at $52.24. The overall price target consensus is at $59.50...
2024-05-15 08:00:04 ET Benjamin Burnett from Stifel Nicolaus issued a price target of $83.00 for ACLX on 2024-05-15 06:37:00. The adjusted price target was set to $83.00. At the time of the announcement, ACLX was trading at $50.62. The overall price target consensus is a...